A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents
about
Is fat taste ready for primetime?The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intakeRegulation of nausea and vomiting by cannabinoids and the endocannabinoid systemTamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug DevelopmentCB1R antagonist increases hepatic insulin clearance in fat-fed dogs likely via upregulation of liver adiponectin receptors2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspectiveInhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behaviorCentral mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in ratsNew insights on the role of the endocannabinoid system in the regulation of energy balance.A runner's high depends on cannabinoid receptors in mice.The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.Treatment options for obesity and potential therapies on the horizonEndocannabinoid signal in the gut controls dietary fat intake.The endocannabinoid system as a key mediator during liver diseases: new insights and therapeutic openingsAM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner.Prevention of Diet-Induced Obesity Effects on Body Weight and Gut Microbiota in Mice Treated Chronically with Δ9-TetrahydrocannabinolAnti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats.Fasting stimulates 2-AG biosynthesis in the small intestine: role of cholinergic pathwaysControlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes.The anti-nausea effects of CB1 agonists are mediated by an action at the visceral insular cortex.Therapeutic modulation of cannabinoid lipid signaling: metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonistProtection from Radiation-Induced Pulmonary Fibrosis by Peripheral Targeting of Cannabinoid Receptor-1.Cannabinoid discrimination and antagonism by CB(1) neutral and inverse agonist antagonists.Development and preliminary validation of a plate-based CB1/CB2 receptor functional assayEndocannabinoids in the GutPeripheral Pathways in the Food-Intake Control towards the Adipose-Intestinal Missing Link.Diuretic effects of cannabinoid agonists in mice.Pathophysiology of NASH: perspectives for a targeted treatment.Regulation of nausea and vomiting by cannabinoidsRimonabant redux and strategies to improve the future outlook of CB1 receptor neutral-antagonist/inverse-agonist therapies.Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders.The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives.Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on Δ(9)-tetrahydrocannabinol challenge tests.Cannabinoid signaling in health and disease.Modulation of food consumption and sleep-wake cycle in mice by the neutral CB1 antagonist ABD459CB1 antagonism produces behaviors more consistent with satiety than reduced reward value in food-maintained responding in ratsInverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats.Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects.Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.
P2860
Q22337316-791B51D0-3F10-47E8-AE8A-689559634DC0Q26850858-7D6F2595-EAC0-4F24-8BC8-7ED6B72F4490Q28301264-DC921096-BDB9-4C92-A1FF-2352788BF9D0Q28554883-206C2458-6670-490E-9D6F-C7BDD36DAA08Q28610813-2AE3E414-0AEA-48E0-A452-7EBD3A5D53DCQ33781776-5206F175-584C-4409-B471-929E88A76C47Q33844872-27D46A80-D9F7-4E7D-96AC-CDEA4395ACC5Q34131412-6493894E-7F22-47EE-9076-108FEBB6F537Q34168253-19BA118B-E86A-4420-BACF-F1EDABAB9843Q34494301-98866178-1FF2-4BB4-8546-3E842D9270BDQ34496926-F08644F8-05BC-4390-BB01-2200E9504E28Q34504906-CC2EBDC0-D46B-4588-95C0-6F2948E9E495Q35111291-809EE4B3-728A-4EDE-BDCB-6C7BB05DD151Q35149416-F05FE43F-DDA3-4426-AEA4-D3A6536A3D13Q35193292-CFB9DB83-9E1A-4A0E-96A5-87D559161A72Q35484505-102CEA7F-0973-4BAA-A0E0-EDBB684F9F61Q35860227-EE8F36AD-B96E-4BBF-9CCF-8AF5435A0B99Q36147328-4F6AF0B6-35E0-47B6-9AE9-86FE181581C1Q36339330-92A437D3-960B-4BAF-9597-B6A800ADFE41Q36373581-3956AC7D-819E-419B-9FC2-D8C6D2FC348EQ36382982-86059442-D40A-4E2B-B141-99257D284E12Q36385052-34771C17-FFCA-4878-80ED-535BDA4F1972Q36548944-8688A4E6-7AEA-4A25-A7C8-03FF38DCDDDEQ36642428-A118408A-2493-464B-AC64-FC43FDE1627EQ36915759-57D607F7-11F8-4C6E-82F2-057B6E69FBEFQ37083154-542B53F4-02D9-48DB-A452-8E63FC21C406Q37408131-E47806DF-ABDE-46D7-ACCD-2E3EA3C9C0D7Q37413414-1456AC9F-EA31-4B09-B876-DF1CCFBD3562Q37699476-899FA147-33F7-40E5-A4D7-CD82650F9FDCQ37822831-60A7CFF9-A7FB-4E79-B4F9-CA44B7A1A717Q37862977-D8114165-40D0-4E85-92F9-E5CE9959CD90Q38025166-0CFD8DF2-4CA2-460D-A56F-EA12B19597F1Q38124458-425C84C0-8784-474C-BC67-620E5A593FB1Q38937489-3F1AA1E2-95CC-4B93-B453-49E94EB02008Q39163671-714568C8-0A4C-4BBA-B592-F3394D9E6ADFQ41152430-E9062508-B6C5-4CB0-B3AD-3E067730D578Q41155245-96BE6ED2-345E-4FB7-A92A-4D11036A34F0Q41682319-AFD501CB-8808-44DA-ACD8-61EEBC000276Q41893598-CAC14C53-BAD2-4FA6-9FE7-6C9957818845Q41907106-B5426E44-181B-47A8-8A97-860311E97241
P2860
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A novel peripherally restricte ...... not cause malaise, in rodents
@ast
A novel peripherally restricte ...... not cause malaise, in rodents
@en
A novel peripherally restricte ...... not cause malaise, in rodents
@nl
type
label
A novel peripherally restricte ...... not cause malaise, in rodents
@ast
A novel peripherally restricte ...... not cause malaise, in rodents
@en
A novel peripherally restricte ...... not cause malaise, in rodents
@nl
prefLabel
A novel peripherally restricte ...... not cause malaise, in rodents
@ast
A novel peripherally restricte ...... not cause malaise, in rodents
@en
A novel peripherally restricte ...... not cause malaise, in rodents
@nl
P2093
P2860
P921
P1476
A novel peripherally restricte ...... not cause malaise, in rodents
@en
P2093
A P Chambers
C L Limebeer
K A Sharkey
L A Parker
V K Vemuri
P2860
P304
P356
10.1111/J.1476-5381.2010.00908.X
P407
P577
2010-10-01T00:00:00Z